Rinvoq (Upadacitinib) for Psoriasis

Overview
Rinvoq is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with active psoriatic arthritis who either cannot tolerate or who have not had a sufficient response to a type of biologic drug called a TNF inhibitor. Rinvoq is also referred to by its drug name, upadacitinib.

Rinvoq is a Janus kinase, or JAK, inhibitor. It is believed to work by inhibiting Janus kinases, chemicals involved in signaling the immune system to attack the tissues.

How do I take it?
Prescribing information states that Rinvoq is taken orally once daily. Rinvoq is available in tablet form.

Side effects
The FDA-approved label for Rinvoq lists common side effects including upper respiratory infections, nausea, cough, fever, headache, and acne.

Rare but serious side effects listed for Rinvoq include serious infection, sudden cardiac death, heart attack, stroke, and blood clots.

For more details about this treatment, visit:

Rinvoq — Abbvie
https://www.rinvoq.com